Lung perfusion imaging in nuclear medicine with 99mTc: a comprehensive survey of radiopharmaceuticals

Read full text Summarise with VIRAT
Authors: Hassan Zareian, Mehrnaz Mardazad, Mahshid Kiani, Nafise Pourshafagh, Fateme Karimi, Mehdi Shafiee Ardestani
Cited by: 0
References: 57

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Technetium-99 m-labeled macroaggregated albumin ([⁹⁹ᵐTc]Tc-MAA) is the standard agent for lung perfusion imaging in pulmonary embolism (PE). Limitations related to particle consistency, preparation procedures, and blood-derived origin have prompted the development of alternative non-blood-derived tracers. MAIN BODY: A narrative review of studies up to August 2025 was performed. Candidate radiopharmaceuticals were evaluated for pulmonary localization, physicochemical properties, quality control characteristics, radiopharmacy practicality, kit-based preparation, and preclinical or clinical validation. Biodegradable microspheres, synthetic colloids, starch-based microparticles, and small-molecule complexes demonstrated promising lung uptake. Most tracers, however, lacked standardized preparation, kit compatibility, or validation in PE-relevant models. Starch-based microparticles emerged as the most translationally promising, showing practical workflow and favorable biodistribution. CONCLUSION: No non-blood-derived ⁹⁹ᵐTc tracer currently matches [⁹⁹ᵐTc]Tc-MAA for routine lung perfusion imaging. Future development requires standardized, pharmacopeia-aligned tracers, head-to-head comparisons, and systematic evaluation in early-phase clinical trials.

Fields of Study & Subjects

Radiopharmaceutical Chemistry and Applications Venous Thromboembolism Diagnosis and Management Medical Imaging Techniques and Applications

Publication details

Journal / source
EJNMMI Radiopharmacy and Chemistry
Volume
11
Issue
1
Pages
32
Publication date
31 March 2026
Language
EN